Healthcare
QuidelOrtho Corporation(QDEL)
Live Price
Offline$13.67
+4.11% today
1Y Change
-48.90%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $860.00M
- Revenue Growth
- -1.9%
- EPS Growth
- +45.4%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
QuidelOrtho Corporation (QDEL) is a Healthcare stock with a market cap of $860.00M and listed on NASDAQ. The stock last traded around $13.67 and down 48.9% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -1.9%, EPS growth of +45.4%, a dividend yield of 0.0%. What stands out right now is revenue -1.9%, EPS +45.4%, free cash flow +26.0% with operating margin -33.7% and ROIC -18.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines QDEL price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-1.9% vs +7.6% peer median
Operating Margin
Below sector median
-33.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -1.9% and EPS is at +45.4%, with operating margin around -33.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -1.7% | +0.8% | +39.6% |
2026 Feb 11, 2026 | +7.0% | -17.6% | -18.0% | -37.8% |
2025 Nov 5, 2025 | +56.9% | -22.3% | -17.5% | +1.6% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QDEL
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
QDEL Max Drawdown
-71.85%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QDEL and SPY.
Company Overview
QuidelOrtho Corporation
NASDAQ Global Select
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.
- Leadership
- Brian J. Blaser
- IPO Date
- Feb 1, 1991
- Employees
- 6.6k
- Street Address
- 9975 Summers Ridge Road
- Mailing
- San Diego, CA, 92121
- Region
- San Diego, CA, US
- Reporting Currency
- USD
- Investor Line
- 858 552 1100
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.3
- Price/Book
- 0.4
Growth
- Revenue
- -1.9%
- EPS
- +45.4%
- Free Cash Flow
- +26.0%
Profitability
- Gross Margin
- 46.7%
- Operating Margin
- -33.7%
- Net Margin
- -41.5%
- ROE
- -46.4%
- ROIC
- -18.5%
Balance Sheet
- Debt/Equity
- 1.46
- Current Ratio
- 1.50
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.